Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.

Chiesa, Camila - Perez-Torrado, Valentina - Mezzano, Rossana - Vazquez, Carolina - Criscuolo, Zelika - Serra, Marcelo - Marambaud, Philippe - Escande, Carlos - Ruiz, Santiago

Resumen:

Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT.

Detalles Bibliográficos
2026
Agencia Nacional de Investigación e Innovación
Brain vascular malformation Consorsium
National Institute of Health
vascular pathology
BMP9-ALK1-SMAD signaling
endothelial cell
Hereditary Hemorrhagic Telangiectasia
arteriovenous malformation
Ciencias Médicas y de la Salud
Medicina Clínica
Sistemas Cardíaco y Cardiovascular
Inglés
Institut Pasteur de Montevideo
IPMON en REDI
https://hdl.handle.net/20.500.12381/5572
Acceso abierto
Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)
_version_ 1881639880391393280
author Chiesa, Camila
author2 Perez-Torrado, Valentina
Mezzano, Rossana
Vazquez, Carolina
Criscuolo, Zelika
Serra, Marcelo
Marambaud, Philippe
Escande, Carlos
Ruiz, Santiago
author2_role author
author
author
author
author
author
author
author
author_facet Chiesa, Camila
Perez-Torrado, Valentina
Mezzano, Rossana
Vazquez, Carolina
Criscuolo, Zelika
Serra, Marcelo
Marambaud, Philippe
Escande, Carlos
Ruiz, Santiago
author_role author
bitstream.checksum.fl_str_mv 710ccfef5cb01d54b75d1d847d6b6b7b
a35f8fdbe7364cb667d79d24a1efd010
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
bitstream.url.fl_str_mv https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/2/license.txt
https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/1/Abstract%2016th%20HHT%20Scientific%20conference.pdf
collection IPMON en REDI
dc.creator.none.fl_str_mv Chiesa, Camila
Perez-Torrado, Valentina
Mezzano, Rossana
Vazquez, Carolina
Criscuolo, Zelika
Serra, Marcelo
Marambaud, Philippe
Escande, Carlos
Ruiz, Santiago
dc.date.accessioned.none.fl_str_mv 2026-06-08T15:56:42Z
dc.date.available.none.fl_str_mv 2026-06-08T15:56:42Z
dc.date.issued.none.fl_str_mv 2026-06-03
dc.description.abstract.none.fl_txt_mv Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT.
dc.description.sponsorship.none.fl_txt_mv Agencia Nacional de Investigación e Innovación
Brain vascular malformation Consorsium
National Institute of Health
dc.identifier.anii.es.fl_str_mv FMV_1_2021_1_166595
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12381/5572
dc.language.iso.none.fl_str_mv eng
dc.rights.*.fl_str_mv Acceso abierto
dc.rights.license.none.fl_str_mv Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.source.es.fl_str_mv HHT International Scientific Conference
dc.source.none.fl_str_mv reponame:IPMON en REDI
instname:Institut Pasteur de Montevideo
instacron:Institut Pasteur de Montevideo
dc.subject.anii.none.fl_str_mv Ciencias Médicas y de la Salud
Medicina Clínica
Sistemas Cardíaco y Cardiovascular
dc.subject.es.fl_str_mv vascular pathology
BMP9-ALK1-SMAD signaling
endothelial cell
Hereditary Hemorrhagic Telangiectasia
arteriovenous malformation
dc.title.none.fl_str_mv Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
dc.type.es.fl_str_mv Documento de conferencia
dc.type.none.fl_str_mv info:eu-repo/semantics/conferenceObject
dc.type.version.es.fl_str_mv Enviado
dc.type.version.none.fl_str_mv info:eu-repo/semantics/submittedVersion
description Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT.
eu_rights_str_mv openAccess
format conferenceObject
id IPMON_7de68462197745e71d6c6dd0833dca65
identifier_str_mv FMV_1_2021_1_166595
instacron_str Institut Pasteur de Montevideo
institution Institut Pasteur de Montevideo
instname_str Institut Pasteur de Montevideo
language eng
network_acronym_str IPMON
network_name_str IPMON en REDI
oai_identifier_str oai:redi.anii.org.uy:20.500.12381/5572
publishDate 2026
reponame_str IPMON en REDI
repository.mail.fl_str_mv msarroca@pasteur.edu.uy
repository.name.fl_str_mv IPMON en REDI - Institut Pasteur de Montevideo
repository_id_str 9421_2
rights_invalid_str_mv Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)
Acceso abierto
spelling Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)Acceso abiertoinfo:eu-repo/semantics/openAccess2026-06-08T15:56:42Z2026-06-08T15:56:42Z2026-06-03https://hdl.handle.net/20.500.12381/5572FMV_1_2021_1_166595Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT.Agencia Nacional de Investigación e InnovaciónBrain vascular malformation ConsorsiumNational Institute of HealthengHHT International Scientific Conferencereponame:IPMON en REDIinstname:Institut Pasteur de Montevideoinstacron:Institut Pasteur de Montevideovascular pathologyBMP9-ALK1-SMAD signalingendothelial cellHereditary Hemorrhagic Telangiectasiaarteriovenous malformationCiencias Médicas y de la SaludMedicina ClínicaSistemas Cardíaco y CardiovascularNitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.Documento de conferenciaEnviadoinfo:eu-repo/semantics/submittedVersioninfo:eu-repo/semantics/conferenceObjectInstitut Pasteur de Montevideo//Ciencias Médicas y de la Salud/Medicina Clínica/Sistemas Cardíaco y CardiovascularChiesa, CamilaPerez-Torrado, ValentinaMezzano, RossanaVazquez, CarolinaCriscuolo, ZelikaSerra, MarceloMarambaud, PhilippeEscande, CarlosRuiz, SantiagoLICENSElicense.txtlicense.txttext/plain; charset=utf-85124https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/2/license.txt710ccfef5cb01d54b75d1d847d6b6b7bMD52ORIGINALAbstract 16th HHT Scientific conference.pdfAbstract 16th HHT Scientific conference.pdfChiesa et alapplication/pdf28837https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/1/Abstract%2016th%20HHT%20Scientific%20conference.pdfa35f8fdbe7364cb667d79d24a1efd010MD5120.500.12381/55722026-06-08 12:56:43.842oai:redi.anii.org.uy:20.500.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://hdl.handle.net/20.500.12381/575Organismo científico-tecnológicohttps://pasteur.uy/https://redi.anii.org.uy/oai/requestmsarroca@pasteur.edu.uyUruguayopendoar:9421_22026-06-08T15:56:43IPMON en REDI - Institut Pasteur de Montevideofalse
spellingShingle Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
Chiesa, Camila
vascular pathology
BMP9-ALK1-SMAD signaling
endothelial cell
Hereditary Hemorrhagic Telangiectasia
arteriovenous malformation
Ciencias Médicas y de la Salud
Medicina Clínica
Sistemas Cardíaco y Cardiovascular
status_str submittedVersion
title Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
title_full Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
title_fullStr Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
title_full_unstemmed Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
title_short Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
title_sort Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
topic vascular pathology
BMP9-ALK1-SMAD signaling
endothelial cell
Hereditary Hemorrhagic Telangiectasia
arteriovenous malformation
Ciencias Médicas y de la Salud
Medicina Clínica
Sistemas Cardíaco y Cardiovascular
url https://hdl.handle.net/20.500.12381/5572